Inflammation and the Metabolic Syndrome in Psychosis

精神病炎症与代谢综合征 摘要文本 代谢综合征（MetS）是一组与代谢相关的危险因素， 动脉粥样硬化性心血管疾病的发病率和死亡率。MetS在患者中非常常见 患有精神病，心血管疾病是该患者人群死亡的主要原因。的 MetS也与低度炎症状态相关。血液白色血细胞（WBC）计数-偶数 在正常范围内-作为炎症的标志。精神病与增加的 炎症，包括WBC总数和分类计数增加。的不良代谢作用 非典型抗精神病药物，增加代谢综合征的风险，可能会加强血液炎症反应的异常水平， 标记。几个大的基于人群的样本发现， 与MetS风险及其个体标准相关。与一般人群相比， 关于炎症和精神病中代谢综合征之间的联系，特别是基线是否 炎症标志物水平可预测抗精神病药物治疗的代谢副作用。这 应用解决了这些重要的知识差距。主要目标是系统地执行 关于炎症与流行和偶发MetS之间关系的综述和荟萃分析， 精神病患者，包括来自精神分裂症开放转化科学的未发表数据 （OPTICS）项目，杨森和NIMH之间的开放科学倡议。此R 03应用程序：1）具有 目的与NIMH的战略重点一致，即临床上有用的生物标志物，可预测 疾病轨迹，2）是一个严格设计的系统性综述和荟萃分析，使用未发表的数据 来自OPTICS项目，研究一种新的潜在生物标志物，可以在治疗前识别- 抗精神病药物不良心脏代谢作用风险增高的精神病患者，以及 代表了为这些患者提供个性化医疗方法的“下一步”，以及3）支持 L30和K23获奖者到R系列研究员的职业过渡，与NIH的下一步一致 一代研究者倡议。

INFLAMMATION AND THE METABOLIC SYNDROME IN PSYCHOSIS ABSTRACT TEXT The metabolic syndrome (MetS) is a constellation of metabolic risk factors associated with the development of atherosclerotic cardiovascular disease morbidity and mortality. The MetS is highly common in patients with psychosis, and cardiovascular disease is the leading cause of mortality in this patient population. The MetS is also associated with a state of low-grade inflammation. Blood white blood cell (WBC) counts—even within the normal range—serve as a marker of inflammation. Psychosis is associated with increased inflammation, including increased total and differential WBC counts. The adverse metabolic effects of atypical antipsychotics, which increase MetS risk, may potentiate aberrant levels of blood inflammatory markers. Several large population-based samples found that total and differential WBC counts were associated with risk of the MetS and its individual criteria. Compared to the general population, relatively less is known about associations between inflammation and the MetS in psychosis, especially whether baseline levels of inflammatory markers predict incident metabolic adverse effects of antipsychotic treatment. This application addresses these important knowledge gaps. The primary goals are to perform systematic reviews and meta-analyses of the relationship between inflammation and prevalent and incident MetS in patients with psychosis, including unpublished data from the Open Translational Science in Schizophrenia (OPTICS) Project, an open-science initiative between Janssen and the NIMH. This R03 application: 1) Has Aims congruent with NIMH's strategic focus on clinically useful biomarkers that predict change across the trajectory of illness, 2) Is a rigorously designed systematic review and meta-analysis using unpublished data from the OPTICS Project to investigate a novel potential biomarker that may identify—prior to treatment— patients with psychosis at heightened risk for incident adverse cardiometabolic effects of antipsychotics, and represents a “next-step” towards personalized medicine approaches for these patients, and 3) Supports the career transition of an L30 and K23 awardee to an R-series Investigator, consistent with the NIH's Next Generation Researchers Initiative.